Cargando…
Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy
Lymphoid malignancies, mainly including lymphocytic leukemia and lymphoma, are a group of heterogeneous diseases. Although the clinical outcome of patients has been significantly improved with current immuno-chemotherapy, definitive biomarkers remain to be investigated, particularly those reflecting...
Autores principales: | Zhao, Xia, Zhang, Wei, Wang, Li, Zhao, Wei-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101819/ https://www.ncbi.nlm.nih.gov/pubmed/24252620 http://dx.doi.org/10.1186/2050-7771-1-24 |
Ejemplares similares
-
NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy
por: Grondona, Paula, et al.
Publicado: (2018) -
Histone Modifications and Their Targeting in Lymphoid Malignancies
por: Fernández-Serrano, Miranda, et al.
Publicado: (2021) -
Novel agents and biomarkers for acute lymphoid leukemia
por: Zhao, Yanmin, et al.
Publicado: (2013) -
Development of venetoclax for therapy of lymphoid malignancies
por: Zhu, Huayuan, et al.
Publicado: (2017) -
Highlights: Lymphoma microenvironment: Current progress of the tumor microenvironment in lymphoid malignancies
por: Karube, Kennosuke
Publicado: (2021)